Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Iovance Biotherapeutics (IOVA) over the last 13 years, with Q3 2025 value amounting to -$91.3 million.

  • Iovance Biotherapeutics' Profit After Tax fell 923.14% to -$91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$397.7 million, marking a year-over-year increase of 300.1%. This contributed to the annual value of -$372.2 million for FY2024, which is 1617.82% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Profit After Tax stood at -$91.3 million, which was down 923.14% from -$111.7 million recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Profit After Tax high stood at -$78.6 million for Q4 2024, and its period low was -$116.4 million during Q4 2023.
  • Over the past 3 years, Iovance Biotherapeutics' median Profit After Tax value was -$107.4 million (recorded in 2023), while the average stood at -$103.2 million.
  • In the last 5 years, Iovance Biotherapeutics' Profit After Tax skyrocketed by 3247.75% in 2024 and then crashed by 1499.16% in 2025.
  • Iovance Biotherapeutics' Profit After Tax (Quarter) stood at -$116.4 million in 2023, then skyrocketed by 32.48% to -$78.6 million in 2024, then fell by 16.12% to -$91.3 million in 2025.
  • Its Profit After Tax was -$91.3 million in Q3 2025, compared to -$111.7 million in Q2 2025 and -$116.2 million in Q1 2025.